Sycamore Labs | $65,000,000 | (Mar 31, 2026)
Deccan AI | $25,000,000 | (Mar 31, 2026)
Stedi | $50,000,000 | (Mar 31, 2026)
Sapreme Technologies BV
Netherlands
- Bilthoven, Utrecht
- 11/10/2021
- Series A
- $17,300,000
Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.
Our solution to endosomal entrapment has the potential to re-open myriad drug development pathways for macromolecule therapeutics lacking efficacy and to explore new targets considered “undruggable” by permeabilizing endo-lysosomal membranes, allowing trapped macromolecules to be released, increasing target engagement without negatively impacting the plasma membrane integrity.
- Industry Biotechnology Research
- Website https://sapreme-technologies.com/
- LinkedIn https://www.linkedin.com/company/sapreme-technologies-bv/
Related People
Guy HermansFounder
Belgium -
Merelbeke, Flemish Region
Experienced biopharmaceutical industry executive, with a strong background in target discovery/validation, early stage biologics R&D and platform technology validation and commercialization.
Specialties: Drug target discovery, target validation, product opportunity evaluation, lead discovery project management, clinical immunology, technology development, antibody engineering
OpenBox AI | $5,000,000 | (Mar 31, 2026)
Qodo | $70,000,000 | (Mar 31, 2026)
Starcloud | $170,000,000 | (Mar 31, 2026)
Valinor(1) | $25,000,000 | (Mar 31, 2026)
Mars Men | $27,500,000 | (Mar 31, 2026)
Scalvy | $13,900,000 | (Mar 27, 2026)
SIGMAS | $1,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)